Litigation Details for ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)

ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)

Docket		Date Filed	2014-06-03
Court	District Court, D. New Jersey	Date Terminated	2016-08-01
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	Defendant	Referred To	Karen M. Williams
Patents	6,774,122; 7,456,160; 8,329,680; 8,466,139
Link to Docket	External link to docket

Details for ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-03	1		THE PATENTS-IN-SUIT 17. United States Patent No. 6,774,122 (the “’122 patent”), entitled…to the expiration of AstraZeneca’s U.S. Patent Nos. 6,774,122, 7,456,160, 8,329,680, and 8,466,139. … COUNT I: INFRINGEMENT OF U.S. PATENT NO. 6,774,122 31. Plaintiffs hereby reallege…INFRINGEMENT OF U.S. PATENT NO. 6,774,122 42. Plaintiffs hereby reallege…12. This is a civil action for patent infringement under the patent laws of the United States, Title	External link to document
2016-03-30	194		ORDER, Covenant Not to Sue Regarding U.S. Patent Nos. 6,774,122, 7,456,160, 8,329,680, and 8,466,139. Signed…2014 1 August 2016 1:14-cv-03547 830 Patent Defendant District Court, D. New Jersey	External link to document
2016-06-20	261		COUNT IX (U.S. Patent No. 6,774,122 Is Not Unenforceable) … Patent, the ’160 Patent, the ’680 Patent, and the ’139 Patent as the …Sagent’s counterclaims as to the ’160 patent because that patent is no longer alleged to be infringed …Sagent’s counterclaims as to the ’160 patent because that patent is no longer alleged to be infringed … ’122 patent, and that AstraZeneca UK Limited is the beneficial owner of the ’122 patent. AstraZeneca	External link to document